Global Companion Diagnostics for Oncology Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027
Report Code: KNJ1028626 No. of Pages: 137 Category: Medical Devices
Publisher: Date of Publish:
Publisher: Date of Publish:
Executive Summary
According to GRD Survey data, the global Companion Diagnostics for Oncology market was valued at million US$ in 2020 and is expected to reach million US$ by the end of 2027, growing at a CAGR of % in the forecast period between 2021 and 2027.
This report studies the Companion Diagnostics for Oncology market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Companion Diagnostics for Oncology in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Market Snapshot, By Application
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
Main Market Players Analyzed in this report, including:
Thermo Fisher Scientific
Roche
Qiagen
Illumina
Foundation Medicine
BioMérieux
ArcherDX
Amoy Diagnostics
Agilent Technologies
Abbott
The study objectives of this report are:
To study and analyze the global Companion Diagnostics for Oncology market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Companion Diagnostics for Oncology market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Companion Diagnostics for Oncology manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Companion Diagnostics for Oncology market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Companion Diagnostics for Oncology submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Companion Diagnostics for Oncology are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Companion Diagnostics for Oncology Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Companion Diagnostics for Oncology Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Companion Diagnostics for Oncology
3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Companion Diagnostics for Oncology Sales Channel and Distributors Analysis
3.3.1 Companion Diagnostics for Oncology Sales Channel
3.3.2 Companion Diagnostics for Oncology Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Pharmaceutical and Biopharmaceutical Companies
3.4.2 Major Buyers in Contract Research Organizations
3.5 Companion Diagnostics for Oncology Manufacturing Cost Structure Analysis
4 Market Segment: by Type
4.1 Companion Diagnostics for Oncology Type Introduction
4.1.1 Polymerase Chain Reaction (PCR)
4.1.2 Next-Generation Sequencing (NGS)
4.2 Global Companion Diagnostics for Oncology Sales by Type 2016-2021
4.3 Global Companion Diagnostics for Oncology Revenue by Type 2016-2021
4.4 Global Companion Diagnostics for Oncology Price by Type 2016-2021
5 Market Segment: by Application
5.1 Companion Diagnostics for Oncology Type Introduction
5.1.1 Pharmaceutical and Biopharmaceutical Companies
5.1.2 Contract Research Organizations
5.1.3 Laboratories
5.1.3 Others
5.2 Global Companion Diagnostics for Oncology Sales by Application 2016-2021
5.3 Global Companion Diagnostics for Oncology Revenue by Application 2016-2021
5.4 Global Companion Diagnostics for Oncology Price by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Companion Diagnostics for Oncology Market by Region
6.1.1 Global Companion Diagnostics for Oncology Sales by Regions
6.1.2 Global Companion Diagnostics for Oncology Revenue by Regions
6.2 North America Companion Diagnostics for Oncology Market 2016-2021
6.3 Europe Companion Diagnostics for Oncology Market 2016-2021
6.4 Asia Pacific Companion Diagnostics for Oncology Market 2016-2021
6.5 South America Companion Diagnostics for Oncology Market 2016-2021
6.6 Middle East and Africa Companion Diagnostics for Oncology Market 2016-2021
7 North America
7.1 North America Companion Diagnostics for Oncology Market by Country 2016-2021
7.1.1 North America Companion Diagnostics for Oncology Sales by Country
7.1.2 North America Companion Diagnostics for Oncology Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Companion Diagnostics for Oncology Market by Country 2016-2021
8.1.1 Europe Companion Diagnostics for Oncology Sales by Country
8.1.2 Europe Companion Diagnostics for Oncology Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Companion Diagnostics for Oncology Market by Country 2016-2021
9.1.1 Asia Pacific Companion Diagnostics for Oncology Sales by Country
9.1.2 Asia Pacific Companion Diagnostics for Oncology Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Companion Diagnostics for Oncology Market by Country 2016-2021
10.1.1 South America Companion Diagnostics for Oncology Sales by Country
10.1.2 South America Companion Diagnostics for Oncology Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Companion Diagnostics for Oncology Market by Country 2016-2021
11.1.1 Middle East and Africa Companion Diagnostics for Oncology Sales by Country
11.1.2 Middle East and Africa Companion Diagnostics for Oncology Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 Thermo Fisher Scientific
12.1.1 Thermo Fisher Scientific
Company Information
12.1.2 Thermo Fisher Scientific
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.1.3 Thermo Fisher Scientific
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Thermo Fisher Scientific
Key Development
12.2 Roche
12.2.1 Roche
Company Information
12.2.2 Roche
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.2.3 Roche
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Roche
Key Development
12.3 Qiagen
12.3.1 Qiagen
Company Information
12.3.2 Qiagen
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.3.3 Qiagen
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Qiagen
Key Development
12.4 Illumina
12.4.1 Illumina
Company Information
12.4.2 Illumina
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.4.3 Illumina
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Illumina
Key Development
12.5 Foundation Medicine
12.5.1 Foundation Medicine
Company Information
12.5.2 Foundation Medicine
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.5.3 Foundation Medicine
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Foundation Medicine
Key Development
12.6 BioMérieux
12.6.1 BioMérieux
Company Information
12.6.2 BioMérieux
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.6.3 BioMérieux
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 BioMérieux
Key Development
12.7 ArcherDX
12.7.1 ArcherDX
Company Information
12.7.2 ArcherDX
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.7.3 ArcherDX
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 BioMérieux
Key Development
12.9 Agilent Technologies
12.9.1 Agilent Technologies
Company Information
12.9.2 Agilent Technologies
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.9.3 Agilent Technologies
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Agilent Technologies
Key Development
12.8 Amoy Diagnostics
12.8.1 Amoy Diagnostics
Company Information
12.8.2 Amoy Diagnostics
Companion Diagnostics for Oncology Product Portfolio, Specification and Application
12.8.3 Amoy Diagnostics
Companion Diagnostics for Oncology Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Amoy Diagnostics
Key Development
13 Global Companion Diagnostics for Oncology Market Forecast by Region by Type and by Application
13.1 Global Companion Diagnostics for Oncology Sales, Revenue Forecast 2022-2027
13.2 Global Companion Diagnostics for Oncology Forecast by Regions
13.2.1 Global Companion Diagnostics for Oncology Sales Forecast by Region 2022-2027
13.2.2 Global Companion Diagnostics for Oncology Revenue Forecast by Region 2022-2027
13.3 Global Companion Diagnostics for Oncology Forecast by Type
13.3.1 Global Companion Diagnostics for Oncology Sales Forecast by Type 2022-2027
13.3.2 Global Companion Diagnostics for Oncology Revenue Forecast by Type 2022-2027
13.3.3 Global Companion Diagnostics for Oncology Price Forecast by Type 2022-2027
13.4 Global Companion Diagnostics for Oncology Forecast by Application
13.4.1 Global Companion Diagnostics for Oncology Sales Forecast by Application 2022-2027
13.4.2 Global Companion Diagnostics for Oncology Revenue Forecast by Application 2022-2027
13.4.3 Global Companion Diagnostics for Oncology Price Forecast by Application 2022-2027
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com